<DOC>
	<DOC>NCT00452907</DOC>
	<brief_summary>Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia</brief_summary>
	<brief_title>ACT MALI: Treatment of Malaria Based on Combination Therapies</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Body weight &gt; 5kg Residence in the investigator site area for the duration of the trial Axillary temperature ≥ 37,5°C at Day 0 Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000 asexual parasites /µl of blood Danger signs or signs of severe malaria Other severe illnesses Allergy to one of the drugs Pregnant women The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>